Related Experiment Videos
The therapeutic efficacy of AC-1370 against experimental infections in mice
Abstract:
The therapeutic efficacy of AC-1370, a new cephalosporin, was compared with that of cefoperazone in experimental infections in mice. For intraperitoneal infections caused by Escherichia coli and Klebsiella pneumoniae, the efficacy of AC-1370 was inferior to that of cefoperazone. On the other hand, AC-1370 was more potent than cefoperazone against pseudomonal infections. The MICs of AC-1370 against the test strains, however, were inferior or equivalent to those of cefoperazone. Serum and peritoneal exudate levels of AC-1370 in infected mice were more durable than those of cefoperazone. The relationship between AC-1370 and neutrophils was investigated. The efficacy of AC-1370 was more dependent on neutrophils than that of cefoperazone. AC-1370 did not enhance the neutrophil functions of migration and phagocytosis to any significant extent.
Insights
AC-1370, a new cephalosporin, showed less efficacy than cefoperazone against E. coli and K. pneumoniae but was more potent against Pseudomonas infections in mice. Its therapeutic effect was more dependent on neutrophils.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Cephalosporins are a class of antibiotics used to treat bacterial infections.
- Cefoperazone is a third-generation cephalosporin with broad-spectrum activity.
- AC-1370 is a novel cephalosporin with potential therapeutic applications.
Purpose of the Study:
- To compare the therapeutic efficacy of AC-1370 with cefoperazone in murine models of infection.
- To investigate the pharmacokinetic properties and neutrophil dependency of AC-1370.
Main Methods:
- Experimental infections were induced in mice using Escherichia coli, Klebsiella pneumoniae, and Pseudomonas species.
- Therapeutic efficacy was assessed by comparing survival rates and bacterial clearance.
- Minimum Inhibitory Concentrations (MICs) were determined.
- Serum and peritoneal fluid levels of antibiotics were measured.
- The role of neutrophils in AC-1370's efficacy was evaluated.
Main Results:
- AC-1370 demonstrated inferior efficacy to cefoperazone against E. coli and K. pneumoniae intraperitoneal infections.
- AC-1370 exhibited superior potency against pseudomonal infections compared to cefoperazone.
- MICs for AC-1370 were equivalent or inferior to cefoperazone.
- AC-1370 achieved more durable serum and peritoneal exudate levels than cefoperazone.
- The efficacy of AC-1370 was found to be more dependent on neutrophils than cefoperazone, without significantly enhancing neutrophil migration or phagocytosis.
Conclusions:
- AC-1370 presents a distinct activity profile, being more effective against Pseudomonas infections but less so against E. coli and K. pneumoniae compared to cefoperazone.
- The enhanced efficacy of AC-1370 against certain pathogens may be linked to its pharmacokinetic properties and neutrophil dependency.
- Further research is warranted to elucidate the mechanisms underlying AC-1370's neutrophil-dependent activity and its clinical potential.